| Range: | 28.14-41.61 | Vol Avg: | 719362 | Last Div: | 0 | Changes: | 0.84 |
| Beta: | 0.77 | Cap: | 1.94B | Currency: | USD | Exchange: | NASDAQ |
| Sector: | Healthcare | IPO: | Wed Aug 19 2020 | Empoloyees: | 246 | ||
| CUSIP: | 413197104 | CIK: | 0001802665 | ISIN: | US4131971040 | Country: | US |
| CEO: | Dr. Jeffrey M. Dayno M.D. | Website: | https://www.harmonybiosciences.com | ||||
HRMY 34.07 Stock Price Harmony Biosciences Holdings, Inc.
Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, develops and commercializes therapies for patients with rare neurological disorders in the United States. Its product, WAKIX is a medication for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is based in Plymouth Meeting, Pennsylvania.
Stock Details
Positive 0.40
HARMONY BIOSCIENCES TO PARTICIPATE IN UPCOMING INVESTOR CONFERENCES
PLYMOUTH MEETING, Pa. , Nov. 21, 2024 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. (...
prnewswire.com·Thu Nov 21 2024
Positive 0.27
Harmony Biosciences Holdings, Inc. Investigated by Shareholder Rights Advocates - Investors Should Contact Levi & Korsinsky Regarding Potential Securities Law Violations - HRMY
NEW YORK, NY / ACCESSWIRE / November 20, 2024 / Levi & Korsinsky notifies investors that i...
accesswire.com·Wed Nov 20 2024
Positive 0.35
Harmony Biosciences: sNDA Of WAKIX Brings Additional Value Inflection Points
Harmony Biosciences Holdings, Inc.'s potential expansion of WAKIX targeting patients with ...
seekingalpha.com·Mon Nov 11 2024
Positive 0.27
Harmony Biosciences Holdings, Inc. Investigated by Shareholder Rights Advocates - Investors Should Contact Levi & Korsinsky Regarding Potential Securities Law Violations - HRMY
NEW YORK, NY / ACCESSWIRE / November 1, 2024 / Levi & Korsinsky notifies investors that it...
accesswire.com·Fri Nov 01 2024
Positive 0.36
HRMY vs. REGN: Which Stock Is the Better Value Option?
Investors interested in stocks from the Medical - Biomedical and Genetics sector have prob...
zacks.com·Thu Oct 31 2024
Positive 0.26
Harmony Biosciences Holdings, Inc. (HRMY) Q3 2024 Earnings Call Transcript
Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY ) Q3 2024 Earnings Conference Call October...
seekingalpha.com·Tue Oct 29 2024
Positive 0.45
Harmony Bio, The No. 1 Biotech Stock, Surged On Its 'High-Quality' Beat
Harmony Biosciences stock jumped Tuesday on the biotech company's "high-quality" third-qua...
investors.com·Tue Oct 29 2024
Positive 0.27
Harmony Biosciences Holdings, Inc. Investigated by Shareholder Rights Advocates - Investors Should Contact Levi & Korsinsky Regarding Potential Securities Law Violations - HRMY
NEW YORK, NY / ACCESSWIRE / October 29, 2024 / Levi & Korsinsky notifies investors that it...
accesswire.com·Tue Oct 29 2024
Positive 0.27
Harmony Biosciences Holdings, Inc. Investigated by Shareholder Rights Advocates - Investors Should Contact Levi & Korsinsky Regarding Potential Securities Law Violations - HRMY
NEW YORK, NY / ACCESSWIRE / October 23, 2024 / Levi & Korsinsky notifies investors that it...
accesswire.com·Wed Oct 23 2024
Positive 0.27
Harmony Biosciences Holdings, Inc. Investigated by Shareholder Rights Advocates - Investors Should Contact Levi & Korsinsky Regarding Potential Securities Law Violations - HRMY
NEW YORK, NY / ACCESSWIRE / October 10, 2024 / Levi & Korsinsky notifies investors that it...
accesswire.com·Thu Oct 10 2024
Positive 0.49
Is Harmony Biosciences (HRMY) Stock Undervalued Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings est...
zacks.com·Wed Sep 25 2024
Positive 0.39
HRMY vs. REGN: Which Stock Should Value Investors Buy Now?
Investors looking for stocks in the Medical - Biomedical and Genetics sector might want to...
zacks.com·Tue Sep 24 2024
About The Monevue
The content provided on this site is for informational purposes only and does not constitute financial, investment, or professional advice. We are not registered investment advisors or financial planners, and we do not provide recommendations or advice on buying, selling, or holding any particular stocks or securities. Any investment decisions should be made based on your own research and consultation with a qualified financial professional. We are not responsible for any financial loss or damages incurred from reliance on the information provided on this site. Please invest responsibly and seek professional advice when needed.
• Powered by StackThrow